Display options
Cite
Matsushita Y, Hayashida S, Morishita K, et al. Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases. Mol Clin Oncol. 2015;4(2):191-194doi: 10.3892/mco.2015.696.
Matsushita, Y., Hayashida, S., Morishita, K., Sakamoto, H., Naruse, T., Sakamoto, Y., Yamada, S. I., Yanamoto, S., Fujita, S., Ikeda, T., & Umeda, M. (2016). Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases. Molecular and clinical oncology, 4(2), 191-194. https://doi.org/10.3892/mco.2015.696
Matsushita, Yuki, et al. "Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases." Molecular and clinical oncology vol. 4,2 (2016): 191-194. doi: https://doi.org/10.3892/mco.2015.696
Matsushita Y, Hayashida S, Morishita K, Sakamoto H, Naruse T, Sakamoto Y, Yamada SI, Yanamoto S, Fujita S, Ikeda T, Umeda M. Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases. Mol Clin Oncol. 2016 Feb;4(2):191-194. doi: 10.3892/mco.2015.696. Epub 2015 Dec 07. PMID: 26893859; PMCID: PMC4734225.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Feb;4(2):191-194. doi: 10.3892/mco.2015.696. Epub 2015 Dec 07.

Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases.

Molecular and clinical oncology

Yuki Matsushita, Saki Hayashida, Kota Morishita, Hiroshi Sakamoto, Tomofumi Naruse, Yuki Sakamoto, Shin-Ichi Yamada, Souichi Yanamoto, Shuichi Fujita, Tohru Ikeda, Masahiro Umeda

Affiliations

  1. Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan.
  2. Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan; Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621, Japan.
  3. Department of Oral Pathology and Bone Metabolism, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan.

PMID: 26893859 PMCID: PMC4734225 DOI: 10.3892/mco.2015.696

Abstract

Medication-related osteonecrosis of the jaw (ONJ) is caused by antiresorptive (bisphosphonates and denosumab) and antiangiogenic agents, with the first report of denosumab-related ONJ emerging in 2010. To date, although certain case reports on denosumab-related ONJ have been published, those of ONJ caused by a single application of the drug are scarce. In addition, only one report described the histopathological features of this condition, although not completely; only the sequestrum resected by conservative surgery was evaluated. Although conservative treatment is recommended, the effectiveness of extensive surgery in the early stages of bisphosphonate-related ONJ has been described in recent years. Here we report the clinical and histopathological features of denosumab-related ONJ caused by single application of the drug, which was treated by extensive surgery in two patients. Histopathological analysis revealed a decreased number of osteoclasts in viable bone around the sequestrum, and these appeared morphologically immature, as indicated by the presence of very few nuclei. These findings are different from those for bisphosphonate-related ONJ and may assist in elucidating the mechanism underlying denosumab-related ONJ. Furthermore, extensive surgery may be effective for the management of this condition.

Keywords: bisphosphonate osteonecrosis; cathepsin K; denosumab; medication-related osteonecrosis of the jaw; osteoclasts; osteocytes

References

  1. Bone. 2008 Aug;43(2):222-9 - PubMed
  2. Int J Clin Exp Med. 2014 Oct 15;7(10):3707-9 - PubMed
  3. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56 - PubMed
  4. J Clin Oncol. 2011 Mar 20;29(9):1125-32 - PubMed
  5. Aust Dent J. 2014 Dec;59(4):516-9 - PubMed
  6. N Engl J Med. 2009 Jan 1;360(1):53-62 - PubMed
  7. Osteoporos Int. 2014 Jan;25(1):393-5 - PubMed
  8. J Craniomaxillofac Surg. 2013 Jun;41(4):e65-9 - PubMed
  9. J Oral Maxillofac Surg. 2010 May;68(5):959-63 - PubMed
  10. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6 - PubMed
  11. Int J Clin Oncol. 2014 Apr;19(2):403-10 - PubMed
  12. J Craniomaxillofac Surg. 2013 Oct;41(7):694-8 - PubMed
  13. Br J Oral Maxillofac Surg. 2010 Apr;48(3):221-3 - PubMed
  14. Int J Oral Maxillofac Surg. 2015 May;44(5):568-85 - PubMed
  15. Bone. 1997 Feb;20(2):81-6 - PubMed
  16. N Engl J Med. 2006 Feb 23;354(8):821-31 - PubMed
  17. Oral Oncol. 2014 Nov;50(11):1049-57 - PubMed
  18. Nat Rev Rheumatol. 2009 Jun;5(6):341-6 - PubMed
  19. Bone. 2011 Apr 1;48(4):677-92 - PubMed
  20. J Biol Chem. 2010 Sep 3;285(36):28164-73 - PubMed
  21. J Oral Maxillofac Surg. 2014 Apr;72(4):702-16 - PubMed
  22. Lancet. 2011 Mar 5;377(9768):813-22 - PubMed
  23. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):785-91 - PubMed
  24. J Thorac Oncol. 2012 Dec;7(12):1823-9 - PubMed
  25. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 - PubMed

Publication Types